261 related articles for article (PubMed ID: 23117021)
1. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.
Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021
[TBL] [Abstract][Full Text] [Related]
2. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
J Pharm Sci; 2014 Nov; 103(11):3448-3456. PubMed ID: 25219511
[TBL] [Abstract][Full Text] [Related]
3. Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit.
Mohaghegh M; Tafaghodi M
Pharm Dev Technol; 2011 Feb; 16(1):36-43. PubMed ID: 20082579
[TBL] [Abstract][Full Text] [Related]
4. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
5. Structure function attributes of gold nanoparticle vaccine association: effect of particle size and association temperature.
Barhate GA; Gaikwad SM; Jadhav SS; Pokharkar VB
Int J Pharm; 2014 Aug; 471(1-2):439-48. PubMed ID: 24907644
[TBL] [Abstract][Full Text] [Related]
6. Preparation and in vivo study of dry powder microspheres for nasal immunization.
Tafaghodi M; Rastegar S
J Drug Target; 2010 Apr; 18(3):235-42. PubMed ID: 19929307
[TBL] [Abstract][Full Text] [Related]
7. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
8. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
Pirouzmand H; Khameneh B; Tafaghodi M
Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
[TBL] [Abstract][Full Text] [Related]
9. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
[TBL] [Abstract][Full Text] [Related]
10. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.
Klein K; Mann JF; Rogers P; Shattock RJ
J Control Release; 2014 Jun; 183():43-50. PubMed ID: 24657807
[TBL] [Abstract][Full Text] [Related]
11. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties.
Wang T; Jiang H; Zhao Q; Wang S; Zou M; Cheng G
Int J Pharm; 2012 Oct; 436(1-2):351-8. PubMed ID: 22721849
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-based immunopotentiation via tetanus toxoid-loaded gelatin and aminated gelatin nanoparticles.
Sudheesh MS; Vyas SP; Kohli DV
Drug Deliv; 2011 Jul; 18(5):320-30. PubMed ID: 21351824
[TBL] [Abstract][Full Text] [Related]
13. Chitosan microparticles as oral delivery system for tetanus toxoid.
Ahire VJ; Sawant KK; Doshi JB; Ravetkar SD
Drug Dev Ind Pharm; 2007 Oct; 33(10):1112-24. PubMed ID: 17852363
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
Vila A; Sánchez A; Janes K; Behrens I; Kissel T; Vila Jato JL; Alonso MJ
Eur J Pharm Biopharm; 2004 Jan; 57(1):123-31. PubMed ID: 14729088
[TBL] [Abstract][Full Text] [Related]
15. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
[TBL] [Abstract][Full Text] [Related]
16. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
18. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A.
Sarti F; Perera G; Hintzen F; Kotti K; Karageorgiou V; Kammona O; Kiparissides C; Bernkop-Schnürch A
Biomaterials; 2011 Jun; 32(16):4052-7. PubMed ID: 21377204
[TBL] [Abstract][Full Text] [Related]
19. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.
Tafaghodi M; Jaafari MR; Sajadi Tabassi SA
Eur J Pharm Biopharm; 2006 Oct; 64(2):138-45. PubMed ID: 16797952
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity.
Mann JF; Scales HE; Shakir E; Alexander J; Carter KC; Mullen AB; Ferro VA
Methods; 2006 Feb; 38(2):90-5. PubMed ID: 16414269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
